Lifeline Cell Technology, LLC

Jeffrey Janus, President, has a proven track record extending over eighteen years of creating profitable commercial cell based businesses and building corporate value as a result. He was one of the leaders in the development and commercialization of Clonetics Corporation and the Clonetics brand of human cell products for both research and clinical use. That company was successfully sold in 1995 after ten consecutive years of profitable growth exceeding 20%. Mr. Janus foresaw the need for human cells in therapy and created businesses in the contract manufacturing of human cells and culture media and human cells for clinical use. He has organized businesses providing unique research products using living cells to conduct drug screening in the pharmaceutical industry, product testing in the consumer products industry and basic research at Universities and Government laboratories. Critical staff from Clonetics Corporation agreed to join Lifeline to pursue the advancement of stem cell product development and manufacture for research and therapeutic use and to re-establish a successful management team. Mr. Janus has a MBA and a Bachelor's degree in Biochemistry.

Elena Revazova, Ph.D., M.D., Director of Research and Development, is one of the world's experts in creating immortal cell lines. Dr. Revazova was a leading cell biologist in the Soviet Union before coming to the U.S. eight years ago. She is now a US citizen. Dr. Revazova has successfully established human stem cell lines from unfertilized oocytes. She has personally created or supervised the creation and patenting of over 50 different cell models that include, stomach, colon, liver, renal, lung, muscle and skin cells and has also created stable human cell lines from tumors of various organs and tissues Dr. Revazova’s access to the leading scientists and research institutes in the former Soviet Union has proven to be an invaluable asset to Lifeline. Those relationships are expected to continue to add value, even though the Company’s base of operations is in the United States.

Jeremy Hammond, Director of Quality Control, has over eighteen years of experience developing human cell based products and the quality control systems critical for their manufacture. He created and implemented the quality control systems that were responsible for making Clonetics products world renown for consistency and reproducibility. These quality control systems are the standard for companies currently manufacturing human cell based products. Mr. Hammond is expert in the field of both serum-containing and serum-free media formulations and in the purification of human cells, fields critical for therapeutic applications of cell culture technology.

Alexa Dillberger – Director of Sales, has over 25 years experience in the commercialization and sales of research products to researchers in the biotechnology industry, including 11 years leading sales for normal human cell and media products. She has laboratory experience, especially in the isolation and derivation of specific human cells from tissue. Her technical and sales background make Alexa aware of the issues that are important to researchers in the field and uniquely able to set up the technical service that is so important to make Lifeline a resource to its customers..

William B. Adams, Managing Member and CFO, has 30 years of experience in the corporate consulting and financing arenas. Mr. Adams has provided seed capital and secondary and bridge financing to numerous start-up companies both individually and as a manager of various private investment partnerships. He is a Managing Member of Convergent Investors, LLC (also known as "CV-I"). Mr. Adams served as CFO of Neurion Pharmaceuticals, Inc., a CV-I portfolio company. Through investments prior to the formation of Convergent Ventures, Mr. Adams is a co-founder of WaveTec Vision Systems, an ophthalmic device company and Lifeline Cell Technology, LLC. He served as President of Wm. Adams Accountancy Corporation and was a founder of Dimensional Planning Group, a management consulting and financial planning company. Previously, Mr. Adams was an accountant at Ernst & Ernst (now Ernst & Young). Mr. Adams holds a B.S. in Accounting from California State University, Long Beach and is on the alumni Board of Ernst & Young in Los Angeles.

Hoyt Matthai, Manufacturing Advisor, has over 20 years of experience directing and establishing manufacturing facilities for the production of cell culture products, class I and III medical devices, biologicals, and cell based pharmaceuticals. Mr. Matthai has extensive experience in developing and validating manufacturing systems for human, animal, and genetically modified cell cultures. Under his direction, cell culture products have been manufacturing for pharmaceutical use, clinical In Vitro Diagnostics, and research use in large scale operations including an 82,000-sq. ft. manufacturing facility, a 65,000-sq. ft. warehouse, and over 230 personnel. His industry work experience includes HEM Research, Flow Laboratories, BioWhittaker (Clonetics), Cambrex, Neuralstem, MetriGenix, Gene Logic, ATCC and Lifeline. Mr. Matthai received his undergraduate degree from Florida State University and his MS degree from Hood College, Frederick, Maryland.

Scott Boyer, Marketing Advisor, is the Executive Director of Marketing for Utah State University Extension and marketing consultant to the cell culture industry. He has over 18 years of successful cell culture marketing, market research, product management, and customer care experience in academic, government, clinical, and pharmaceutical applications. Specific products include normal human cell systems for research, classical media for research, class I and III cell cultures for clinical applications. His industry work experience includes Clonetics, BioWhittaker, Cambrex, HyClone, Fisher Scientific, and Lifeline. Mr. Boyer received his undergraduate degree from San Diego State University, and an M.B.A. from Frostburg State University, Frostburg, Maryland.